---
schema_version: "secwatch.filing_event.v1"
accession: "0001321732-24-000058"
form_type: "8-K"
ticker: "PEN"
cik: "0001321732"
company_name: "Penumbra Inc"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T16:45:21.983363+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Penumbra Q1 revenue $278.7M (+15.4% YoY); U.S. thrombectomy up 35.2%; reaffirms FY24 guidance

## Summary
- Revenue $278.7M, up 15.4% YoY (15.2% constant currency); U.S. thrombectomy $150.3M, +35.2%.
- GAAP operating income $12.1M vs $8.0M YoY; non-GAAP operating income $19.3M.
- Adjusted EBITDA $37.6M (13.5% margin); cash & investments rose $24.3M sequentially.
- FY2024 guidance reaffirmed: total revenue growth 16-20%, U.S. thrombectomy growth 27-30%.
- Gross margin improved to 65.0% from 62.6% on favorable product mix and productivity.

## SEC filing metadata
- accession: 0001321732-24-000058
- form_type: 8-K
- ticker: PEN
- cik: 0001321732
- company_name: Penumbra Inc
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321732/000132173224000058/0001321732-24-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321732/000132173224000058/pen-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001321732-24-000058
- JSON: https://secwatch.observer/filing/0001321732-24-000058.json
- Plain text: https://secwatch.observer/filing/0001321732-24-000058.txt

## Key facts
- Earnings Releases
  Penumbra Inc reported the first fiscal quarter ended March 31, 2024 results: revenue $278.7 million. Guidance reaffirmed.
  - Period: the first fiscal quarter ended March 31, 2024
  - Revenue: $278.7 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024. • Revenue of $278.7 million in the first quarter of 2024, an increase of 15.4% or 15.2% in constant currency 1 , compared to the first quarter of 2023. • U.S. thrombectomy revenue of $150.3 million in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321732/000132173224000058/0001321732-24-000058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.